Atlas Trials

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Clinical trial NCT05132023 · COMPLETED

Trial details

NCT number
NCT05132023
Sponsor
Genuine Research Center, Egypt
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2019-03-26
Primary completion
2019-04-02
Enrollment
26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.